Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05230907 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1- PF-05230907 or Placebo | EXPERIMENTAL | - |
| Cohort 2- PF-05230907 or Placebo | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 1 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 2 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 3 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 4 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 5 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-05230907 | DRUG | A single intravenous dose of 3 μg/kg |
| Placebo | DRUG | A single intravenous dose of matched placebo |
| Placebo for PF-05230907 | DRUG | 0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose |
Inclusion Criteria: * Healthy male of females * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs) and \<120 kg (265 lbs). * Japanese subjects who have four biologic Japanese grandparents born in Japan. Exclusion Criteria: * Pregnant or nursing females. * Femal...
PF-05230907 is an investigational monoclonal antibody being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development and has been studied in healthy volunteers. The drug is not approved and remains in clinical testing.
PF-05230907 has been studied in healthy volunteers in Phase 1 clinical trials. The studies evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is investigational and has not been approved for any medical condition.
PF-05230907 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development.
PF-05230907 is in Phase 1 clinical development. Two Phase 1 studies have been completed, both involving healthy volunteers. The drug is investigational and has not received regulatory approval.
PF-05230907 has been studied in two completed Phase 1 trials. NCT01897142 enrolled 49 healthy volunteers in Belgium, and NCT02537002 enrolled 17 healthy Japanese subjects in the United States. Both trials were single-dose studies.
PF-05230907 is not FDA approved. It is an investigational monoclonal antibody in Phase 1 clinical development. Two Phase 1 trials in healthy volunteers have been completed, but the drug has not been approved for any use.